The 20 Most Disruptive Healthcare Solution providers - PowerPoint PPT Presentation

About This Presentation

The 20 Most Disruptive Healthcare Solution providers


With an idea to acknowledge the fast-growing companies, contributing extraordinarily to the revolution of disruption in healthcare, we bring to you the special edition of “The 20 Most Disruptive Healthcare Solution Providers 2018”. – PowerPoint PPT presentation

Number of Views:193


Transcript and Presenter's Notes

Title: The 20 Most Disruptive Healthcare Solution providers

1 November 2018
Laurie Goodman CEO Board Manager
BIOTECHNOLOGIES Developing a Next-Generation 3D
Tissue Processing Platform by Leveraging CLARITY
(No Transcript)
(No Transcript)
Pooja M. Bansal Anish Miller Ashwini S.
Deshpande Aishwarya Nawandhar Devasish, Sneha,
Sayali David King Amol Kamble Poonam, Shweta
Editor-in-Chief Senior Editor Managing
Editor Executive Editor Contributing
Editors Visualiser Art Design Head Art
Design Assistant
Co-designer Paul Belin Art Picture Editor Karan
Peter Collins Marry DSouza Mark Williams John,
Amy, Bill, Sarah Jacob Smile Swapnil
Patil David, Robert Alina Sege Prashant
Chevale Rahul, Gemson, Swati Eric Smith Tanaji
Business Development Manager Marketing Manager
Business Development Executive Sales
Executives Technical Head Assistant Technical
Head Technical Consultants Digital Marketing
Manager Assistant Digital Marketing
Manager SME-SMO Executives Research Analyst
Circulation Manager November, 2018 Corporate
Insights Care Insights Success Media and
Technology Pvt. Ltd. Of?ce No. 510, 513, 5th
Floor, Rainbow Plaza, Shivar Chowk, Pimple
Saudagar, Pune, Maharashtra 411017 Phone - India
91 7410079881/ 82/ 83/ 84/ 85 Email For Subscription
Insights Care Insights Success Media Tech LLC
555 Metro Place North, Suite 100, Dublin, OH
43017, United States Phone - (614)-602-1754 Email For Subscription
Follow us on h
ttps// We are also
available on Copyright 2018 Insights Success
Media and Technology Pvt. Ltd., All rights
reserved. The content and images used in this
magazine should not be reproduced or transmitted
in any form or by any means, electronic,
mechanical, photocopying, recording or otherwise,
without prior permission from Insights
success. Reprint rights remain solely with
Insights Success Media and Technology Pvt. Ltd.
Insights Care is powered by Insights Success
Media and Technology Pvt. Ltd.
Kick-Starting Your Way in Healthcare
Editors Column
Istart-ups as well as the big giants in this
sector, and rather disruptively. Yet, there is
nnovation is the key to unlock the future in
every sector. Same is the case with
healthcare. The need of innovation in this
segment is being fed by the numerous
place for more. With so many emerging trends and
changes in healthcare, one question
that comes to the mind of any professional
willing to establish a new business is- How can
it be done in a better way? In healthcare,
success of a business is not determined by only
the ordinary terms. There are some
industry-speci?c points that one has to
consider. To start with, one must know that it
is not a consumer market. In most of the cases,
patients are not the ones paying their own bills
and selecting their own products. Here's where
the doctors and insurance companies play a role
and should be considered as well. Also, the
investment needed in a healthcare start-up is
long term. Even if the company manages to incur
decent amount of money to initiate the business,
there comes a need for second and third and more
rounds of investments required. It is of
signi?cance to have a proper business
model. Another important factor to consider is
the regulations that are to be abided in
healthcare. Various regulations such as HIPAA,
the A?ordable Healthcare Act, and many more are
unavoidable. The companies need to embrace these,
in order to remain in the picture. Alongside,
while thinking of disruptive technology, in
healthcare there are already several giants and
companies present that are working on the same.
It is of bene?t to learn to work with them,
rather than against them. A lot of start-ups do
not think su?ciently over this. There are
various other things to be thought of while
establishing a new business in the healthcare
space. An idea is the path laid to walk through
it is the execution of that idea and to end up
successfully, requires a lot more than just idea
and execution. So, with the right ingredients,
one can embark on this path and
disrupt! Aishwarya Nawandhar Editor
ClearLight Biotechnologies Developing a
Next-Generation 3D Tissue Processing Platform by
Leveraging CLARITY - Cover Story
Behavioral Health Works Restoring Hope for
Families Facing Autism with Premium Service
Clearsense Driving Innovations to Bring an End
to the Era of Disconnected Data
Genpharm A Foremost Pharmaceutical Organization
Offering Tailor- made and Comprehensive
Experts View Why is it important for healthcare
providers to move towards patient- personalised
Proteins are Better Biomarkers than Genes
Science Scoop Never Miss a Dose Medication Apps
HIV Awareness Month HIV Still an Impending
Threat to Mankind
Editors Insight Telemedicine A Revolutionary
Step in Healthcare
Phronetik Unmasking Genetics to Improve Health
Sunny Days In-Home Care Re-shaping the
Healthcare Landscape with In-Home Care
The TeleDentists Delivering Top-notch Dentistry
Services at Your Doorstep in a Cost-effective Way
Innovators Disrupting the Healthcare Industry
Tcircumstance in which an innovation starts
reshaping an industry or a market by making it
he term Disruptive Innovation was ?rst coined
by a Harvard Professor, Clayton M. Christensen.
Today, it is
a word widely heard and spoken across the entire
business landscape. According to Clayton, it is a
convenient, accessible, and a?ordable. The
process initiates in a niche area that may be
inconsequential to the whole market, but
eventually ends up transforming the entire
Healthcare is one of the spheres that highly need
disruptive innovation. With the numerous new
technologies launched, the opportunity for this
is greater than it has ever been. It is expected
that in the future, with disruptive innovation,
patient care will be provided at reduced costs
and improved quality. With an idea to
acknowledge the fast-growing companies,
contributing extraordinarily to the revolution of
disruption in healthcare, we bring to you the
special edition of The 20 Most Disruptive
Healthcare Solution Providers 2018. Featured on
its Cover is ClearLight Biotechnologies. It is
harnessing next generation technologies to
revolutionize the diagnostic, prognostic, and
predictive treatment of disease. Apart from this
insightful cover story, we have also enlisted the
leading companies transforming the healthcare
landscape. This list includes Behavioral Health
Works, a company focused on improving autism and
related-disorder treatment Clearsense, which is
solving all the fundamental problems of data in
healthcare Genpharm, o?ering comprehensive
solutions to the pharmaceutical companies
Phronetik, answering the unanswered questions of
healthcare and advancing precision medicine
Sunny Days In-home Care, providing best-in-class
and a?ordable in- home care services The
Teledentists that has enabled top-notch dental
care anytime, anywhere American
Telepsychiatrists Avera eCARE Bikham
Information Technology Cydar Ltd Direct
Radiology KPMG LLP LiveProcess Livio Health
Group Medivizor NaphCare, Inc. Rethink
Singapore OG Ltd and Zilico. In addition to
this, we have also featured two interesting
articles from the industry experts Stephen
Critchlow and Steven Pelech. To further engage
your thoughts, we have incorporated a few
gripping write-ups from our in-house
editors. Flip through the pages and enjoy a good
(No Transcript)
Next-Generation 3D Tissue Processing Platform by
Leveraging CLARITY
We are developing a novel, next generation
technology platfam fa processing
and visualizing tissue in 3D
Cover Stay
Laurie Goodman, Ph.D. CEO Board Manager
ealthcare presents a paradox
when it comes to innovation.
Although many of the highly
innovative discoveries come at a very swift
pace, ideas that can transform healthcare occur
gradually, over a
prolonged period of time. These gradual
transformations are also known as Disruptive
Innovations. In this, the existing methods or
traditions are improved to increase the quality
of care and simultaneously make it a?ordable by
leveraging the existing or up and coming
technologies. This allows the whole population
to signi?cantly seek the bene?ts of various
healthcare technologies and thereby promoting
population health. Looking at the scenario of
the health space today, disruptive innovation
in healthcare is a signi?cant revolution that
the world needs. A small Biotechnology
startup, ClearLight Biotechnologies, LLC, is
leading the revolution of a positively
disruptive innovation in healthcare. Formerly
At ClearLight, we are focused on improving
as Clearlight Diagnostics, LLC, it was founded in
2014 by Karl Deisseroth, MD, PhD, the inventor
of CLARITY, Optogenetics, and STARmap
technologies and D.H. Chen, Professor of
Bioengineering and Psychiatry Behavioral
Sciences at Stanford University as well as the
Investigator of the Howard Hughes Medical
Institute. ClearLight is an early stage company,
focused on developing automated instrumentation
and associated reagents to simplify and expedite
non-destructive 3-Dimensional (3D) tissue
analysis to facilitate preclinical and clinical
research applications. It is creating a platform
that will enable an end-to-end solution for 3D
analysis of preclinical and clinical models of
disease. It will consist of an automated
multi-sample and individualized 3D tissue
processor paired with optimized biomarker panels
as well as multi-sample imaging and custom 3D
image analysis software. Focus Areas The
current focus of the company is in the area of
oncology prognostic and predictive applications.
In this, it emphasizes on predictive biomarker
applications for immune-oncology T-cell based
drugs as well as standard of care (SOC)
biomarkers. Neuroscience is another area of
interest for ClearLight Biotechnologies. In
neuroscience, it emphasizes on the models of
Alzheimers disease. However, the technology
could be easily applied to any biological area
that relies on 2D thin-section analysis of a
tissue. The Visionary Leader Laurie Goodman,
Ph.D. is the current CEO and Board Manager of
ClearLight Biotechnologies and previously served
as the Chief Scienti?c O?cer since 2015 before
assuming her new role. Dr. Goodman is a seasoned
professional with more than 25 years of
experience in innovative technology development,
clinical cancer diagnostics, and translational
cancer research within the biotechnology
industry. She holds a BS degree in Biology with
a minor in Chemistry from Arizona State
University and a PhD in Cell and Molecular
Biology from University of California Berkeley.
Following a postdoctoral fellowship at
Genentech, she began her career at Lynx
Therapeutics (currently Illumina) where she
initiated and developed a breast cancer
scienti?c program to validate the companys next
generation sequencing platform. Dr. Goodman is
also an author on several key publications and
patents related to analytic and clinical cancer
the future of predictive
She has worked in broad senior level roles
encompassing research and development as well as
clinical and medical a?airs. Prior to joining
ClearLight, Dr. Goodman held the position of
Senior Director of Scienti?c and Medical A?airs
for Biodesix, an innovator of blood-based cancer
diagnostics. She was instrumental in building and
leading the companys ?rst scienti?c and medical
a?airs team, as well as initiating key academic
collaborations in the areas of lung and breast
cancer. Her other senior level roles include
directing the analytic team involved in the CLIA
validation and commercialization of Monogram
Biosciences ?rst oncology diagnostic product,
HERmark. The Problem in the Already Existing
Techniques Current gold standard techniques, for
the analysis of diseased and normal tissues are
outdated and around a century old. It relies on
the analysis of 2D thin-section formalin ?xed
para?n embedded (FFPE) tissue techniques. The
spatial analysis of a potentially heterogeneous
tissue microenvironment can be highly limited by
such techniques, as can the analysis of the
tissue morphology. Furthermore, 2D analysis is
destructive, slide-based, variable and highly
manual, and does not represent the entire
biology. Mathematically speaking, a
single 5-micron tissue section from a 2 cm3
breast carcinoma is exactly the same as the
ratio of a single Manhattan block to all of
Manhattan (adapted from a personal communication
with Dr. Geo?rey Baird MD PhD). It is not
representative of the more comprehensive biology
of that tumor and therefore may hinder
successful treatment outcomes for patients.
Revolutionizing the
biomarker information. Importantly, the
technology enables the storage of samples
inde?nitely for future analysis and the
microscopic imaging capabilities including
confocal, light sheet, and SPIM. The work?ow of
this platform is very simple and includes
treatment of cancer is our goal
  • Embedding the tissue in a hydrogel matrix
  • Removal of light scattering lipids that impede
    the ability to image deeply within a tissue
  • Multiplexed interrogation with directly or
    indirectly ?uorescently labeled antibodies or
    nucleic acids to identify key structural and
    microenvironment biomarkers and refractive index
  • Microscopic imaging of the tissues, using long
    working distance objectives and either confocal,
    light sheet, or SPIM
  • 3D image analysis using Arti?cial Intelligence
    (AI) and machine learning techniques.
  • The development program of the company is a
    combination of external software and hardware
    engineering contractors, as well as strategic
    academic and business partnerships.
  • Team ClearLight
  • The internal team of ClearLight is comprised of a
    Director of Operations, two Directors of
    Research and Development, a Head of Lab
    Operations along with the CEO. In order to keep
    costs to a minimum, the company operates
    primarily with an extensive external network
    support that handle human resources, IT,
    accounting taxes, engineering, animal facility
    CRO, marketing/website support, and legal works
    (corporate and IP). It also has key academic
    collaborations in the area of oncology and
  • Determined to Revolutionize the Future of
  • The mission of ClearLight is to revolutionize the
    diagnostic, prognostic, and predictive treatment
    of disease by enabling next generation
    technologies for non- destructively and
    digitally analyzing diseased and normal tissues
    in 3D. It predicts a similar future of this
    industry as to that of the adoption of next
    generation sequencing (NGS) into clinical
    decision making that took more than 20 years and
    has now become a billion-dollar industry.
  • Dr. Goodman says, We predict a similar steady
    trajectory with

ClearLights Ingenious Solution ClearLight is
developing a next generation instrument, reagent
and software platform for volumetric tissue
processing and 3D image analysis. It is
developing this solution by leveraging the
revolutionary technology called CLARITY, which
is an acronym for Clear Lipid-exchanged
Acrylamide-hybridized Rigid Imaging/Immunostaining
/In- situ hybridization-compatible
Tissue-hYdrogel. CLARITY is a novel approach
that is innovative in both function and utility,
and has been applied broadly to the ?eld of
neurobiology, primarily as a qualitative tool,
says Dr. Goodman. The company believes in the
technology as it enables the formation of a
hydrogel matrix (HM) by crosslinking biological
molecules to a 3D network of hydrophilic
polymers, followed by lipid removal to generate
a transparent and structurally intact tissue.
This tissue retains its original structural
features, can be labeled with macromolecules,
and imaged without destruction of the tissue
morphology. Another advantage of the CLARITY
technology, is that it is compatible with
previously frozen, fresh, formalin-?xed, and
FFPE research and clinical human or rodent
tissue. It is non-destructive, and therefore
fewer samples are required, thus allowing
recapitulation of spatial heterogeneity without
laborious sectioning and registering of samples.
It is compatible with standard nucleic acid and
antibody interrogation techniques. This
technique also allows for multiple
interrogations of a single sample to increase 3D
3D processing and imaging of diseased tissue
being adopted initially into the research use
only (RUO) market and eventually entering the
clinical market as adoption increases and
clinical utility is established. Future
Business Plans Reorganization of leadership in
recent months, has resulted in changes to
several aspects of the company, including a name
change to more accurately portray the revised
business model of the company and future
potential commercialization plan. By the fourth
quarter of 2019 or ?rst quarter of 2020, the
company will be launching a Research Use Only
(RUO) in-house service model along with limited
beta platform testing in the ?eld, for 3-4
academic sites. The in-house custom service model
will be o?ered to academic and pharmaceutical
customers in any ?eld, like preclinical,
clinical drug development, exploratory inclusion
in clinical trials as a means to grow a
pro?table business over the next ?ve years. These
Beta platform studies will allow the company to
validate the system and facilitate the
generation of key clinical utility data,
informing about its future potential. Following
long term adoption of the RUO product by pharma,
academics, and CROs, ClearLight has plans to
enter the Laboratory-Derived Testing Clinical
Market or a Potential FDA-cleared
platform/companion diagnostic with potential
partners, although the plans for this have not
been established at this time. The strategy of
the company is to ?rst establish the RUO and
potential clinical utility and develop the
market for the technology. It foresees this
timeline for FDA approval and clinical utility to
be similar to NGS technology market
adoption. With any new disruptive and
revolutionary technique, adoption takes time and
patience but the rewards are extensive for a
company like ClearLight Biotechnologies since it
holds exclusive intellectual property rights to
develop the CLARITY technology for diagnostic,
prognostic, and predictive future clinical
applications, asserts the CEO.
We aim to
deliver an
way to visualize
and quantify
3D relationships
within the tissue
(No Transcript)
Company Name Management Brief Company Name Management Brief Company Name Management Brief
American Telepsychiatrists John Schae?er CEO American Telepsychiatrists work exclusively through Telepsychiatry and TeleMental Health.
Avera eCARE Deanna Larson CEO Avera eCARE is helping bring advanced medicine to the community so more patients can be treated in a place.
Behavioral Health Works Rob Douk Founder, Chaiman CEO Behavioral Health Works is a leading provider of treatment for individuals with autism and related disorders.
Bikham Information Technology Sonia Dhawan CEO Bikham Information Technology is a Knowledge Process Management company, initiated in 2005.
ClearLight Biotechnologies, LLC clearlightbiotechnologies .com Laurie Goodman CEO Board Manager ClearLight is focused on developing automated instrumentation and associated reagents to simplify and expedite non-destructive 3D tissue analysis to facilitate preclinical and clinical research applications.
Clearsense Charles Boicey Co-founder CIO Clearsense is a technology-based company that provides a platform to solve the fundamental problem of data in healthcare.
Cydar Ltd Tom Carrell CEO Cydar has developed computer vision software that produces real-time automated 3D overlays during X-ray guided procedures.
Direct Radiology John Arias MD Direct Radiology is a physician-owned and operated teleradiology practice.
Genpharm Inc. Karim Smaira Kamel Ghammachi Founders MP Genpharm provides fast-track Market Access to specialty pharmaceutical companies looking to expand into the Middle East and North Africa (MENA) region.
KPMG LLP Lynne Doughtie CEO KPMG is a global network of independent member ?rms o?ering audit, tax, and advisory services.
Company Name Management Brief Company Name Management Brief Company Name Management Brief
LiveProcess Terry Zysk CEO LiveProcess mobile solutions enable real-time healthcare coordination and e?cient emergency response.
Livio Health Group Mike Nathan CEO Founder Livio delivers the care patients need face to face while building a relationship to help them get around obstacles that stand in their way.
Medivizor Tal Givoly CEO Medivizor aims to improve the lives of people with serious or chronic medical conditions and of those who care for them.
NaphCare, Inc. Jim McLane CEO NaphCare is dedicated to implementing cost-e?ective, quality services according to our clients needs.
Phronetik Tania Martin-Mercado President CEO Phronetik o?ers competencies in biotechnology, bioinformatics, data science, arti?cial intelligence and information systems to advance precision medicine and positively impact scienti?c research.
Rethink rethink? Daniel Etra CEO Rethink is a global health technology company providing cloud-based treatment tools, training and clinical supports for individuals with developmental disabilities and their caregivers.
Singapore OG Ltd Ivan Lau CEO Singapore OG Ltd are a leading group of specialist medical practitioners dedicated to womens childrens health and wellness.
Sunny Days In-Home Care David Ellenwood Founder Sunny Days In-Home Care provides high quality, client- centered, and a?ordable in-home care service.
The TeleDentists Maria Kunstadter Michael Sigler, Co-founders The TeleDentists has engineered a cutting-edge cloud-based SaaS service that enables hospitals and urgent care facilities access to a dental specialist.
Zilico Sameer Kothari Chief Executive Director Zilico is developing the next generation of diagnostic devices that remove subjectivity, increase accuracy, and deliver results in real-time.
(No Transcript)
Proteins are Better Biomarkers than Genes
Tplummeted by a million-fold over the last 25
he costs of sequencing the order of nucleotide
hardwired into the structures of these proteins
as dictated by their gene sequences. But, they
are also tightly controlled by reversible
modi?cations after they are initially
manufactured, which are added on by regulatory
proteins that operate within cellular
intelligence systems. While gene sequences can
provide some clues as to the potential functions
and interactions of proteins with each other and
other molecules, this information is extremely
limited. Even now, we do not have a real sense of
what over a third of these diverse proteins do,
and less than 20 of these proteins have
received any real serious attention in research
labs. The disconnect between genetic information
and the actual occurrence of disease is due to
the high impact of environmental factors such as
diet, life style and exposure to agents in the
environment that can a?ect the proteome.
Proteomes are immensely complex and dynamic. For
example, blood plasma may contain as many as
40,000 di?erent protein products, and their
individual concentrations can range over a
trillion-fold. Consequently, tracking proteins
o?ers much better insights into the occurrence
of diseases than genetic pro?ling, and
importantly the opportunity for more rational
therapeutic intervention. While about 21,300
genes encode proteins in the human genome, the
actual number of distinct protein entities in the
proteome may actually exceed several million,
largely due to the range and degree of added
modi?cations and other processing. More than 50
types of modi?cations have been November 2018 18
in the DNA strands found in chromosomes have
The entire sequence of 2.9 billion nucleotide
base-pairs in a single human genome can now be
determined for less than 1000. Complete genomes
of hundreds of thousands of people are expected
to be sequenced over the next decade. While the
acquisition of such genomic knowledge was
originally forecasted to herald better
diagnostics and therapeutic treatments, the
actual deliverables for improved
health care have been disappointing. Excluding
cancer, it has become apparent that only about
10 of the cases of the most common diseases
that a?ict our population have a genetic basis
that can be ascribed to hereditary mutations in
the DNA sequences of speci?c genes. Over 100
million single nucleotide variants appear to
exist in the human population, and perfectly
healthy people appear to commonly harbour about
100 or so serious disease-associated mutations
without any apparent manifestations of these
particular diseases. Studies, with over 50,000
genetically identical twins, have shown no
increased risks for the 24 most common diseases
amongst the twins than for a twin with the
general population. Over 95 of the known 21,300
genes carried in the human genome serve as the
blue-prints for the construction of all of the
cellular proteins, known as the proteome. These
proteins function like molecular robots to
regulate and carry out all of the biochemical
reactions needed to keep cells alive. Their
programming for speci?c tasks is partly
ABOUT THE AUTHOR Dr. Steven Pelech is the
Founder, President, and Chief Scienti?c O?cer
of Kinexus Bioinformatics Corporation, and
concurrently a full professor in the Department
of Medicine at the University of British
Columbia. He was formerly the
founder and president of Kinetek Pharmaceuticals.
He has authored more than 230 scienti?c papers
and created the SigNET on-line Knowledge-bank.
Dr. Steven Pelech Founder, President Chief
Scienti?c O?cer
documented in proteins, with phosphorylation as
the predominant reversible regulatory mechanism.
Over 85 of the proteome is known to be
phosphorylatable at over 250,000 sites, but the
actual number of phosphosites appears to be
closer to a million. The occurrence of these and
other modi?cations in proteins represent a rich
source of biomarkers that may correlate better
with the development of pathologies. Most sites
of known protein modi?cation were originally
revealed by mass spectrometry (MS). However,
apart from being very expensive, MS requires
milligram amount of biological sample material
and is ?nicky for reliable detection of desired
target proteins. For example, out of some 3000
phosphosites in proteins that have been well
documented to be functionally important in the
scienti?c literature, about 22 have not been
reported in any MS studies, whereas another 16
were documented in only one of thousands of MS
analyses that had been performed. Antibodies
have been well proven to be reliable and
e?ective probes for the detection and
quanti?cation of speci?c proteins for their
present and modi?cation states. Over a million
di?erent antibodies against diverse proteinsare
presently commercially available. Furthermore,
the printing of antibodies as individual
microdots on
microscope slide-sized chips with densities
exceeding 5000 spots per chip has paved the way
for biomarker discovery that is easily
translatable into the development of routine
diagnostic tests. Biomarker antibodies can
readily be re-deployed into other tried and true
platforms such as immunoblotting, ELISA, and
immunohistochemistry. Problems with sample
preparation, high background issues, and low
sensitivity of detection initially hampered the
wide- spread adoption of antibody microarrays.
However, recent breakthroughs on all of these
fronts have poised antibody microarrays to
become the most versatile, reproducible, and
cost-e?ective tools in the foreseeable future for
biomarker discovery, using as little as 25
microgram amounts of protein samples from crude,
unfractionated lysates from cells, tissues, and
bio ?uids. High content antibody microarrays can
identify the most appropriate and robust panel
of biomarkers. When used to probe lysate
microarrays printed instead with hundreds of
patient specimen samples on each slide, these
biomarker antibodies can provide accurate,
comprehensive and economical diagnoses for
diseases and for the monitoring of the
e?ectiveness of therapeutic treatments.
19 November 2018
Behavioral Health Works
Restoring Hope for Families Facing Autism with
Premium Service Delivery
Aperson socializes, behaves, or interacts with
utism Spectrum Disorder (ASD) is a neurological
and developmental disorder that impacts the way a
Till date, there is no possible cure for autism.
But some
practices can help improve learning, social
functioning, and quality of life for both
children and adults with this
condition. Behavioral Health Works (BHW) is a
leading provider of treatment for individuals
with autism and related disorders having o?ces
across the United States. The company helps
individuals with autism and other developmental
disabilities reach their potential by working
collaboratively with families, schools, and
relevant professionals. By focusing on ways in
which people respond to their environment
(behavior), it provides opportunities to learn
in speci?c and observable ways, leading to a
positive outcome (health). BHW renders superior
personalized care and service delivery,
maintaining a personal connection with each
family and committing to the advancement of each
and every client. It operates from a CARES
philosophy with the focus on Compassion,
Accountability, Research-based treatments,
E?ective and E?cient changes, and is
consolidated with a family unit
Systems-approach. The Philanthropists Story Dr.
Rob Douk is the Founder, Chairman, and CEO of
BHW. Fleeing death and seeking hope, Robs family
escaped a Cambodian labor camp and migrated to
America in the early 1980s. Building their life
from nothing, his parents taught him how to love
hard and work hard through any situation. Today,
these circumstances best de?ne him. Regarded as
a thought leader in the behavioral health
industry, Rob is a clinician turned social
entrepreneur, executive coach, and ForbesBooks
Featured Author. He is a
Dr. Rob Douk Founder, Chairman, CEO

We strive to bring light into dark places of
this world by delivering premium care and

November 2018 20
serial entrepreneur, having built multiple
successful enterprises, incorporating an
emphasis on making measurable societal changes
in each venture. Rob married his college mate,
Ami, and together they built the Hope Out Loud
Foundation, an international nonpro?t that helps
communities around the world. Rob is known to
coach from a principle of having faith over
fear and he believes that character is the
most important to hire for. BHWs Prudent
Approach BHWs approach to treatment is
naturalistic, using everyday family routines to
foster generalization of skills and to promote
independence right from the start. This approach
is rooted in Applied Behavior Analysis (ABA)
with emphasis on individualized programs,
focusing on each persons strengths and
challenges. Its programs focus on increasing
each clients motivation to learn, making each
session both fun and functional. It also
considers all scienti?cally proven methods when
tailoring each program to ?t the unique needs of
each client. The companys treatment approach in
each of BHWs programs shares the common goal of
teaching individuals the tools necessary to
obtain a better quality of life and to lead a
more independent life. Patients Journey with
BHW When with BHW, patients get more than a
clinical team at their front door. They also get
an administrative team to support them, behind
the scenes, every step of the way. BHW has a
friendly and smart team at the back o?ce, along
with a caring and knowledgeable clinical team to
work with patients using the best and the latest
in clinical research. To keep everything
together, the company has a user-friendly and
robust proprietary technology platform that
captures every BHW program to make what it does
simply a cut above the rest. It has been
servicing across multiple regions with one
united team with a consolidated approach and one
voice. Services and Accomplishments BHW is a
one-stop shop for premium autism service
delivery. It o?ers ABA therapy for the entire
life span, diagnostic clinics, speech and
occupational therapy as well
as social skills groups and counseling. The
company provides a holistic customized program
suited for every individual. From certifying
its therapists with RBT credentials to
responding to the patientsreferrals in less than
2 hours and retaining more than 99 of the
clients, BHW strongly believes in delivering
premium services. This is its biggest
achievement and a testament to all its employees
that deliver on this commitment, day in and day
out. The company has graduated over 70 of its
clients within two years and has a 0 client
relapse rate. Continuously Improving with
TQM Total Quality Management (TQM) is a
philosophy and set of guiding principles that
BHW adopts to focus on continuously improving
the organization, its procedures, and the
services that it provides the clients. TQM
focuses on the needs of the client and on
improving the quality of work and providing a
?nished product. It promotes continuous
monitoring and improvement of company procedures
in order to reduce ine?cient or wasteful
practices. It also involves the entire
organization in the improvement of quality and
also empowers employees at all levels. The
Three Cs of Work Environment Collaboration BHW
prides itself on maintaining a fun, open-door
working environment where collaboration is the
cornerstone of its success. Cause-driven BHW
and its employees embrace that there is more to
a career than a title. What they do actually
matters to them. Celebration Members of BHW,
aka BHWers, support one another through
celebrating their clients successes. The
employees are encouraged to stop by the main o?ce
to enjoy the sta? lounge, take a break, and
indulge in posting on or reading the client
success board. Speaking about the future, Rob
asserts, We would like to serve as many
families in need as we are able to, while
maintaining high quality service delivery for
each family.
21 November 2018
Driving Innovations to Bring an End to the Era
of Disconnected Data
Ipositively disrupted by the technology.
s there anything in common between ?nance and
healthcare? Not much, but both of them are being
innovation is leading the new era of advancement,
and it is much needed. One of the major factors
contributing to this innovation in healthcare is
the use of data science. With the rise in the
number of clinical documents produced every day
and the sensitive nature of medical data, it is
necessary to ?nd a way to collect, organize, and
process the huge amount of data for a more
informed, better healthcare. One of the
companies leading this revolution is Clearsense.
Based in Jacksonville, Florida, Clearsense is a
technology- based company that provides a
platform to solve the fundamental problem of
data in healthcare. The company is an o?shoot of
Optimum Healthcare IT that has been around since
2012. Started as an analytics company,
Clearsense, today, has become a technology
driven organization that is re-imagining and
simplifying data analytics to help healthcare
organizations realize measurable value from
their data.
Charles Boicey Co-founder CIO

The Novel Leader
Charles Boicey is the Co-founder and Chief
Innovation O?cer at Clearsense who has expertise
and experience in a variety of areas. In the
medical ?eld, he specializes in Trauma Critical
Care Nursing. Charles ran the trauma unit at LA
County USC medical center for about 15 years and
then made a transition into Biomedical
Information Systems as well as Biomedical
Engineering. After that, he earned the degrees
in Computer Science and Technology Management
from Stevens Institute of Technology in
We are here to organize the chaos in healthcare

November 2018 22
Hoboken New Jersey and then brought that training
back into healthcare. During his time at the
University of California Irvine, he was the user
of various social media platforms like Facebook,
Twitter, and LinkedIn. He was very fascinated
with their technologies and was set to implement
the same kind of ease in data management for
healthcare. Working on this, he has innovated his
way to the top and led Clearsense to its success
holistic team, which includes clinical
professionals, data scientists, developers, etc.
This has proved to be a great bene?t for the
company. Another one of its key di?erentiators
is that the company has not just learned the
technologies, but has helped develop them. This
brings a huge advantage to the business as well
as its clients. Clearsense provides a full-blown
data ecosystem and has made use of big data.
This has helped it automate the large part of
work processes for its clients. Also, the company
allows the integration and synchronization of
data in the database within days and not weeks,
saving a lot of time and at a?ordable costa. It
also has di?erent governance around the data and
provides adequate security.
Tracing Back the Roadmap to Success
Clearsense started small they had just a couple
of clients who were Charles partners at the
University of California Irvine and Meharry
Medical College. For Meharry Medical College,
the company built a data science institute, and
for the University of California Irvine, it
developed a system for real-time monitoring of
patients in high acuity area. With this,
Clearsense brought all the patients data
together, which includes data from a clinical
environment, laboratory systems, etc. in real
time. This helped make the clinicians aware of
the patients whose health would be slightly
deteriorating so that there can be intervention
before reaching any adverse conditions.
Life at Clearsense
The company fosters a free work environment. At
Clearsense, every individual is accountable and
has the freedom to be innovative and creative.
The company encourages its employees to ask
questions and seek help. It is very important
in a tech company and it kind of goes back to
you know, my clinical time when somebody new
enters the clinical environment, the most
important thing they could say is I dont know,
I cant ?gure this out,and we come in and help
them, says Charles. The company also has a
provision for the employees to work remotely.
There is also a culture of celebration in the
Additionally, the company has also brought in the
legacy data systems and made it available for
folks in health information systems. Another
thing the company did create and provide a
platform for its clients involved in mergers and
acquisitions. It takes the data from the segment
being acquired and brings it into Clearsense and
sends it to the system doing the acquiring after
adequate transformation of that data. Clearsense
does this in a very short period of time,
Whats Ahead?
We are very much in a growth trajectory. We are
signing up more and more healthcare clients as
we go, says the CIO. This will allow its
clients to collaborate with each other. The
company has already started to get involved with
Academia and wants to expand in it further. It is
also getting inquiries from outside of
healthcare. So, it will be potentially moving
outside of healthcare as well, keeping
healthcare at its nexus.
So, started with a few initial clients and have
reached miles already, it plans to expand
What sets it Apart?
The technologies used by Clearsense have just
started to creep in the healthcare market.
Although the company has a couple of competitors
that have started to bring these technologies
in, Clearsense started long back and had already
adapted to these technologies. Alongside, it has a
23 November 2018
Science Scoop
Dose Medication Apps
obile phones, especially smartphones, are doing
to a report published in Annals of Internal
Medicine, September 2012, America loses 100
289 billion in a year due to medication
non-adherence. The situation is graver in case
of chronic illnesses. Treatment of such disease
requires long-term use of medicines. But patients
are seen not adhering to it due to various
reasons. A study from Mayo Clinic states
approximately 50 of patients do not take their
medications as prescribed. This amounts to not
only monetary loss but also health issues. Some
patients end up in emergency rooms because they
did take medicines on time. Even small issues
turn into serious ones if not treated properly.
Doctors have long been advising people to take
their medicines as prescribed. But the results
just dont match up. Keeping a digital eye on
health Mobile apps are now being used to ?ght
this underrated health concern. A huge
population of these patients uses smartphones.
Mobile apps are now being recommended
by November 2018 24
more than what they were intended to do.
Thanks to all the apps that developers around
the world are busy making to simplify the lives.
mobile apps come in all shapes and sizes and do a
myriad of things for smartphone users. While
gaming, social media, and retail apps continue
to rule the charts, health apps are
surely catching up. With people becoming more
health conscious than ever, these apps are also
making their mark. Good health is attributed to
many factors. One needs to have a proper diet,
exercise, routine checkups, and the likes. What
most people tend to neglect intentionally or
unintentionally is the medication routine.
Medicines, be it a lifesaving drug or just a
vitamin pill, is also essential for good health.
Unfortunately, most people tend to forget taking
their pills on time. Some blame it on their
schedule, some dont ?nd the time, some are too
busy to remember, and some, like the elderly,
just forget to take it. According
25 November 2018
doctors and other patients alike to tackle this
menace. These apps are easy to use, mostly free,
and are designed to perform a lot of things for
the patients. These apps have a number of
features to assist patients with drug
adherence. The process is simple and starts with
the patient uploading their prescription or
?lling in the drugs that they are on. They can
then customize alarms, set up emergency numbers,
put a tracker, and other such features. Some apps
even use games to help patients understand the
importance of taking medication on time. Apps
full of features Di?erent apps o?er di?erent
features and sometimes address only a particular
concern. Some apps are free of cost while some
are premium and o?er much-advanced features. But
most apps do the following Set up reminders --
Easiest way to get your dose on time is to set
up alarms. The apps set o? alarms at a de?nitive
time and some even light up the screen with
particular colors to remind the patients of
their pending dose. Some even auto- adjust to
the time zones, so that the patients do not mess
up their dosage when traveling to di?erent parts
of the world. Send messages to caregiver -- Some
apps send messages to the patients caregiver
(mostly family member) and doctor when they miss
a dose. They can then remind the patient to take
their medicine. Manage family health -- Some
apps can help patients deal with multiple
pro?les. This allows one member track the
medicine habits of the entire family. Drug
Interaction Few apps have the feature to let
patients know about drug interactions i.e. if
any two or more of
ones medicines can react and cause issues to
his/her wellbeing. This feature can really help
if one takes over-the- counter drugs with
prescribed medicine. Medical Jargons Mobile
apps can let patients understand medical terms
too. Terms like CR (Controlled Release) printed
on the medicine can often be confusing for
patients. These apps help them crack such
codes. Re?ll reminders These mobile apps remind
patients in advance when they are about to run
out of their prescribed medicines. Contacting
Pharmacy -- A few apps let patients upload their
prescription with the pharmacy and get their
medicines door-step delivered when they need it.
They even allow the pharmacy to cross-check with
the patients doctor to make sure that the
prescribed medicines need to be
continued. Generic Report Some medicine mobile
apps also let patients record their blood
pressure, sugar levels and send them to their
doctors at a ?xed time interval (say once in a
month). These mobile apps are really proving to
be a boon especially for the elderly and those
su?ering from chronic illnesses or illnesses
like Parkinson where the patient genuinely
forgets to take the pills. Timely reminders,
interactive interface, easy-to-use and manage
features, sounds and lights, all make them
suitable for patients across the world. Some
paid and advanced apps even let patients take a
video consultation with their doctors. The world
is getting smarter and better. The world of
medicine apps is slowly recognizing the
opportunity and the what this market can be in
the future. Such apps are surely going to make
this world a healthier place!
- Sneha Sinha November 2018 26
(No Transcript)
A Foremost Pharmaceutical Organization Offering
Tailor-made and Comprehensive Solutions
Gmainly on niche therapeutics and diagnostics for
enpharm is a leading regional pharmaceutical
market access and marketing company focused
rare genetic diseases. The company has partnered
multinational companies that have evidence-based
and innovative drugs looking to expand into the
Middle East and North Africa (MENA) region. The
company operates through an experienced and
dedicated team of medical science liaisons and
key account managers. The companys partnerships
are based on long-term regional commercial
agreements or in-licensing deals under the
Genpharm brand.
Genpharm was established by the two in?uential
Founders Managing Partners, Karim Smaira and
Kamel Ghammachi, whose leadership has been a
consistent presence in the MENA pharmaceutical
sector for over forty years. They both have
successfully occupied several industry roles and
managed large multinational pharmaceutical
organizations in both regional and international
functions. Outshining with its Diverse
Services Genpharm o?ers its expertise to achieve
fast market access for companies looking to
expand into the Middle East region. Being the
exclusive partner for pharmaceutical
organizations, it o?ers every required service to
its clients at the highest standards which
include regulatory, medical and
pharmacovigilance support, quality and logistics,
market access (pricing and reimbursement). It
also dedicates ?eld sta? for them to work
closely with the key stakeholders on disease
awareness, patient support programs, CME events,
scienti?c meetings, advisory boards and expert

Kamel Ghammachi Founder MP
Karim Smaira Founder MP
Our mission is to provide healthcare
organizations with innovative therapeutic
solutions in niche and rare genetic disease
areas, market access strategies and sustainable
commercial solutions

November 2018 28
Genpharm also o?ers consultancy services on
market entry strategies for companies interested
to set up a regional o?ce or that simply want to
understand the commercial potential of their
portfolio and the best strategies to approach
the Middle East market with.
  • solutions that it o?ers, particularly in the
    areas of market access, disease awareness, and
  • Accountability The company wishes its employees
    to be responsible and accountable for their
    actions. It believes that the organizational
    culture of ownership and entrepreneurial spirit
    is extremely di?cult to maintain if employees
    dont feel accountable.
  • Integrity Ethical standards and honesty are core
    values. Genpharm stays transparent internally
    and with its external stakeholders.
  • Teamwork Joining experiences, skills and sharing
    information helps them achieve more together as
    a group than lone individual.
  • Prominent Landmarks in Genpharms Journey
  • Genpharm was a simple entrepreneurial idea and a
    vision shared by the two founders that saw the
    light in 2012.
  • Seeing a signi?cant gap in the rare disease space
    in the Middle East, possessing the regional
    pharmaceutical expertise and a wide global
    network, they decided to turn this into an
    opportunity. With every new initiative, there are
    risks and many nay-sayers. This has been a
    constant motivation to set ambitious objectives
    and surpass them.
  • Genpharm was born out of the idea to become a
    market access provider for small pharmaceutical
    as well as biotech organizations with innovative
    products. The industry reputation of its
    experienced management, the strong brand
    identity acquired and the high quality of the
    work performed, attracted large leading
    corporations such as GSK, Sano? and Novartis
    which embodied a validation for its business
    model and standards as well.
  • Genpharms work has been recognized by working
    references from its partners and also through
    several business and industry awards such as the
    Best Pharmaceutical Market Access Company and
    the Best Pharmaceutical Marketing and
    Consultancy Company in 2016 and 2017 by the MEA
    business awards.
  • Creating Eminence with its Core Values and Vivid
  • Genpharm believes that its core values have been
    its real driving force.
  • Patient Care It is focused on rare diseases,
    caring for the patient and their families are
    central to what we do. This is a key motivator
    that is used in our communication and our
    recruitment. We are usually the only hope that
    these patients have for a better life. This is
    the overarching motivation and the drive behind
    what Genpharm stands for.
  • Innovation Although, the product innovation
    comes from its partners, Genpharm innovates in
    the market

Elevating Environment at Genpharm Being a
start-up business, Genpharm is fully focused on
maintaining an interactive work environment and
o?ers its employees learning on the job through
hands-on experience. Moreover, it tends to look
internally for promotions which are very
motivating. Today, its mid-level management is
composed exclusively of internal
talents. Genpharm maintains a very open
environment for discussion and feedback with
management practicing an open-door policy. The
Management team likes to emphasize the fact
that, If you want to lead people, lead them
from behind. This has led to several internal
promotions, particularly for those that believe
that leadership is what you do when your
manager is not around. Future
Potential Genpharm is all set to continue its
growth trajectory with several new
collaborations, capitalizing on its expertise and
recent track record. The company believes that
the current research and technological
breakthroughs will certainly lead to new
advancements in disease management and even to
curative therapies creating opportunities for its
business development appetite. We are growing
organically at an average of 23 per year. We
see no reason why we cannot continue this
aggressive growth and complete our current
expansion plans. We believe we have an unlimited
potential for pro?table growth, asserts the duo
29 November 2018
Unmasking Genetics to Improve Health
Rmammals. As a race, we have always been
easoning, the power to question and search
answers makes human beings di?erent from other
Tania M President CEO
autodidacts and found solace in learning, growing
teaching. Why and how has it always been
important and
has invoked us to ?nd answers to the unknown? The
  • for this inquisitiveness ranges from personal to
    social, but what is important is the fact that
    the journey to the truth has mostly ended in
    bene?tting the society.
  • It was with this curiosity and a quest for
    answers to unanswered questions that Phronetik
    was founded. What triggered the quest was a
    simple question, How and why does one get a
    disease without any genetic predisposition, no
    family history or adverse lifestyle behaviors?
    Phronetik was started to try and ?nd answer
    these and other questions. The companys name is
    an amalgamation of two Greek words phronesis
    (wisdom) and kinetic (to move) which justi?es
    its quest to leverage technology and innovation
    to improve health care, as they move forward
    with wisdom.
  • A biotechnology company, Phronetik advances
    precision medicine by leveraging OMICS data,
    arti?cial intelligence and informatics to
    improve diagnosis, treatment, and monitoring. It
    also supports translational research with
    particular interest in studies that encompass
    precision medicine. Over years the company has
    been trying to answer the questions with the
    science behind genetic predisposition followed
    by epigenetic studies and population health
    research. The diagnosis and interpretation of
    data and calculation to determine the diseases
    has become the central focus of the company.
  • Never say Never
  • Quitting is unacceptable for Tania
    Martin-Mercado, President CEO, Phronetik, and
    the idea reverberates

We aim to provide answers where there were
previously none

November 2018 30
throughout the company, its employees and its
workings. She started the company in 2013 with
modest beginnings, no outside venture capital or
in?ux of seed money and has toiled hard to bring
it where it stands today. When asked what keeps
her going, she answered, I have questioned my
sanity from time to time. Then I remember why Im
doing this. Maybe, though the e?orts of the
Phronetik team, its University partners and
industry collaborators, we help a family predict
and prevent the onset of disease. She continues
to voice her thoughts, We prevent a death. We
improve quality of care at a practice and quality
of life for a patient. We provide answers where
there were previously none. I believe in what we
are doing wholeheartedly. Spearheaded by its
leader and aptly supported by its sta?,
Phronetik has been designing and re-designing its
o?erings and focus, starting with clinical trial
services and support and broadening to
sequencing and genetic services. It now partners
with a number of CAP/CLIA accredited
laboratories where it o?ers the services of
genomic testing such as diagnostic testing,
predictive genetic tests, pharmacogenomics, and
carrier testing. This OMICS data is then
processed to o?er next-generation sequencing
services and data analysis. It also o?ers
technical support to the solutions. These
professional services include strategic
planning, technology roadmaps, HIPAA risk,
security assessments and more. Its managed
services, SupportDR, is an IT o?ering perfect
for providing technical support for clinical
trials, private practices and other health care
organizations. Speci?c SupportDR services
include public portals, asset and inventory
management, system monitoring and maintenance,
24x7x365 support, remote end-user support and
more. The company is committed to its mission to
provide sustainable, innovative, transformative
and disruptive technologies and services to
support clinical trials, translational research,
and patient-driven outcomes. It o?ers a holistic
approach to translational and clinical
research. The company being anti-silo believes in
informational transparency and necessary
(compliant) data exchange to achieve its goals
of advanced scienti?c discovery, reproducible
studies with data to back them up and accurate,
accessible data for clinicians to improve
healthcare delivery. Phronetik credits its power
to remain ?exible and adaptable to the needs of
the clients as the key to its towering stature
over competitors. It helps in o?ering a wide
array of services to support the clients
Phronetiks e?ort, as it strides along the path
to realizing its values of Good science, good
data, excellence in innovation, and integrity in
all we do, has received recognition and
accolades in many leading magazines. Phronetik
serves the government, life science, hospitals,
ambulatory/private practices, pharmaceutical,
non-pro?t, and community-based
organizations. The company values its employees
like its customers and doesnt hesitate in going
that extra mile to keep them motivated,
innovative and in love with their work. With the
exception of lab work, employees are allowed to
work from home, providing Phronetik access to
the best talent in data science and biotech
regardless of geographical location. Emp
Write a Comment
User Comments (0)